---
schema_version: "secwatch.filing_event.v1"
accession: "0001013762-25-002718"
form_type: "8-K"
ticker: "ABPO"
cik: "0001893219"
company_name: "Abpro Holdings, Inc."
filed_at: "2025-03-26T23:59:59+00:00"
generated_at: "2026-05-24T05:15:51.752518+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Abpro to present first preclinical data for bispecific HER2 x CD3 T-cell engager at AACR 2025

## Summary
- Oral presentation of ABP-102/CT-P72 at AACR 2025 in New Drugs on the Horizon session on April 27, 2025.
- ABP-102/CT-P72 is a tetravalent bispecific HER2 x CD3 T-cell engager developed under a strategic partnership with Celltrion.
- Data are under embargo until presentation; no results disclosed.
- Presenter: Adam J. Pelzek, Ph.D., Associate Director at Abpro.

## SEC filing metadata
- accession: 0001013762-25-002718
- form_type: 8-K
- ticker: ABPO
- cik: 0001893219
- company_name: Abpro Holdings, Inc.
- filed_at: 2025-03-26T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1893219/000101376225002718/0001013762-25-002718-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1893219/000101376225002718/ea023575401-8k_abpro.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001013762-25-002718
- JSON: https://secwatch.observer/filing/0001013762-25-002718.json
- Plain text: https://secwatch.observer/filing/0001013762-25-002718.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.